Meiling Chu

Meiling Chu

Auto-generated profile, based on publicly available information

Meiling Chu

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2025 in Phenomics
Verified
Journal Article
Closed access
PDF file
MCMeiling Chu
Meiling Chu
YZYan Zhang
Yan Zhang
JCJie Chen
Jie Chen
HCHui Cong
Hui Cong
YYYu-lian Yin
Yu-lian Yin
HCHongfeng Chen
Hongfeng Chen

1 September 2023 in Medicine
Verified
Journal Article
Open access
MCMeiling Mm Chu
Meiling Mm Chu
TMTian Meng
Tian Meng
YZYue Mm Zhou
Yue Mm Zhou
LJLan Jin
Lan Jin
QDQiuying Dai
Qiuying Dai
HCHongfeng Chen
Hongfeng Chen
We aimed to explore the molecular mechanism of Ruxian Shuhou prescription in the treatment of triple-negative breast cancer (TNBC) by using network pharmacology. The active components and targets of the prescription were obtained by Traditional Chinese medicine systems pharmacology database. Gencards database, online mendelian inheritance in man database, therapeutic target database, and DRUGBANK database were used to search for the TNBC-related targets. The potential targets of Ruxian Shuhou prescription for TNBC were screened out by the intersection of effective ingredient action targets and disease targets. A herb-active ingredient-target network was constructed and analyzed for key ingredients. A protein-protein interaction network was constructed for studying key targets. Furthermore, gene ontology analysis and Kyoto encyclopedia of genes and genomes pathway enrichment analysis were carried out. Finally, the relationship between key ingredients and key genes was evaluated by molecular docking. The key ingredients of Ruxian Shuhou prescription for the treatment of TNBC may be Quercetin, Luteolin and Kaempferol, while the key therapeutic targets may be protein kinase B, interleukin-6, cellular tumor antigen p53, and vascular endothelial growth factor A. The related signaling pathways were mainly involved in tumor, apoptosis and virus infection, among which the PI3K-Akt signaling pathway was the most closely related to TNBC. Molecular docking showed that the key ingredients had high binding activity with the key targets. The molecular mechanisms of Ruxian Shuhou prescription for TNBC are likely to involve multi-ingredient, multi-target and multi-pathway.

1 August 2023 in Journal of Clinical Densitometry
Verified
Journal Article
Closed access
YYYu-lian Yin
Yu-lian Yin
YFYiwei Fan
Yiwei Fan
MCMeiling Chu
Meiling Chu
HCHongfeng Chen
Hongfeng Chen